BMP-2 Targeting Polypeptide Bone Healing Composition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for large or segmental bone defects, such as bone grafting, are limited by donor site pain, risk of rejection, limited donor supply, and risk of infectious disease transmission, while existing orthopedic substrates fail to facilitate sufficient tissue regeneration.
Innovation Solution
A composition comprising a mammalian growth factor, such as bone morphogenetic protein 2 (BMP-2), combined with a targeting polypeptide that binds to bone or a carrier material like calcium phosphate, to enhance bone healing and tissue regrowth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bone grafting is used to treat large or segmental bone defects, then bone healing is improved, but donor site pain, risk of rejection, limited donor supply, and risk of infectious disease transmission occur
Solution Approach 1:
The patent uses an orthopedic substrate as an intermediary carrier to deliver growth factors and progenitor cells to the bone defect site. This mediator approach eliminates the need for donor bone grafting while providing controlled release of therapeutic agents that promote bone healing and tissue regeneration.
Solution Approach 2:
The invention enables the bone defect site to self-regenerate by delivering growth factors and progenitor cells that stimulate the body's own healing mechanisms. The orthopedic substrate serves as a scaffold that supports autonomous tissue regeneration without requiring continuous external intervention or donor tissue.
2Strength
If orthopedic substrates are used for bone defect treatment, then structural support is provided, but tissue regrowth is insufficient due to loss of progenitor cells within 48 hours and scarcity of progenitor cells
Solution Approach 1:
The patent incorporates progenitor cells and growth factors into the orthopedic substrate before implantation. This preliminary action ensures that progenitor cells are immediately available at the defect site when implantation occurs, preventing their rapid loss within the critical 48-hour window and establishing the foundation for subsequent tissue regeneration.
Solution Approach 2:
The invention changes the biochemical parameters of the orthopedic substrate by incorporating growth factors and progenitor cells. This transforms the substrate from a passive structural support into an active therapeutic delivery system that releases growth factors in controlled amounts to stimulate progenitor cell survival, proliferation, and differentiation, thereby enhancing tissue regrowth.
3Productivity
If growth factors are delivered to bone defect sites, then tissue regeneration is accelerated, but delivery precision is poor leading to loss of progenitor cells within 48 hours
Solution Approach 1:
The patent merges the orthopedic substrate, growth factors, and progenitor cells into a single integrated delivery system. This combination ensures that growth factors are delivered precisely at the defect site together with progenitor cells, maintaining their spatial and temporal relationship to maximize therapeutic effect and prevent progenitor cell loss.
Solution Approach 2:
The invention establishes continuous release of growth factors from the orthopedic substrate over time, rather than a single bolus delivery. This continuous action maintains therapeutic concentrations of growth factors at the defect site, supporting sustained progenitor cell survival and proliferation throughout the critical early healing period and beyond.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition significantly improves bone healing and accelerates tissue regrowth by increasing and sustaining the number of progenitor cells at injury sites, thereby addressing the limitations of current treatments.
Implementation Method 1
a targeting polypeptide (e.g., a polypeptide that binds to bone or a carrier material)
Data Source
AI summary
Provided herein are polypeptides comprising a therapeutic targeted for delivery to an organ or tissue, and uses thereof.